上海晶丰明源半导体股份有限公司监事会 对象名单的审核意见 （截至授予日） 上海晶丰明源半导体股份有限公司（以下简称"公司"）监事会依据《中华 人民共和国公司法》（以下简称" 关于公司 2024 年限制性股票激励计划预留授予激励 简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》 （以下简称"《上市规则》"）、 《科创板上 市公司自律监管指南第 4 号——股权激励信息披露》等相关法律、法规及规范性 文件和《公司章程》的有关规定，对《公司 2024 年限制性股票激励计划预留授 予激励对象名单（截至授予日）》 《公司法》"）、《中华人民共和国证券法》（以下 《证券法》等法律、法 规及规范性文件以及《公司章程》规定的任职资格，符合《管理办法》《上市规 则》规定的激励对象条件，符合本激励计划规定的激励对象范围。 ①最近 12 个月内被证券交易所认定为不适当人选； ②最近 12 个月内被中国证监会及其派出机构认定为不适当人选； ③最近 12 个月内因重大违法违规行为被中国证监会及其派出机构行政处罚 或者采取市场禁入措施； （以下简称"《激励对象名单》"） ...

上海晶丰明源半导体股份有限公司 | | | | | | 获授限制性股 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 获授的限制 | | | | 获授限制性股 | | | | | | | | | | 票占预留授予 | | | | 姓名 | 国籍 | 职务 | 性股票数量 | | 票占授予总量 | | | | | | | | | 时公司总股本 | | | | （万股） | | | | 的比例 | | | | | 一、董事、高级管理人员、核心技术人员 | | | | | 比例 | | | | 董事、副总经理、 | | | | | | | | | 孙顺根 | 中国 | | 0.73 | 0.27% | | 0.01% | | | 核心技术人员 | | | | | | | | | 郜小茹 | 中国 | 核心技术人员 | | 1.67 0.61% | | | 0.02% | | 二、其他激励对象 | | | | | | | | | 中层管理人员以及董事会认为需要被激励 | | | | | | | | | 的其他人员（共 51 | | 人） | | | ...

Core Viewpoint - The Shanghai Jingfeng Mingyuan Semiconductor Co., Ltd. has reviewed and approved the list of incentive recipients for its 2024 restricted stock incentive plan, confirming that the selected individuals meet the necessary qualifications and conditions as per relevant laws and regulations [1][2]. Summary by Relevant Sections Incentive Plan Overview - The incentive plan is in accordance with the Company Law, Securities Law, and other relevant regulations, ensuring that the recipients are appropriate candidates [1][2]. Recipient Qualifications - The recipients include directors, senior management, core technical personnel, middle management, and other individuals deemed necessary for motivation by the board [1]. - The qualifications of the recipients align with the conditions set forth in the Management Measures and Listing Rules, ensuring compliance with legal standards [2]. Exclusions from Incentive Eligibility - Individuals who have been identified as inappropriate candidates by the stock exchange or the China Securities Regulatory Commission (CSRC) within the last 12 months are excluded [2]. - Those who have faced administrative penalties or market entry bans due to significant violations are also ineligible [2]. - Other disqualifications include situations defined by the Company Law and other legal regulations [2].

Core Viewpoint - The company has announced the grant of reserved restricted stock to 53 incentive objects under the 2024 Restricted Stock Incentive Plan, with a grant date set for August 26, 2025, at a price of 27.78 yuan per share, totaling 545,400 shares [1][10][14]. Summary by Sections Restricted Stock Grant Details - The reserved restricted stock grant date is August 26, 2025, with a grant price of 27.78 yuan per share [1][10]. - A total of 545,400 shares will be granted to 53 eligible incentive objects, representing approximately 0.62% of the company's total share capital [4][12]. Decision-Making Process and Disclosure - The decision-making process for the stock grant has been completed, including necessary approvals from the board and supervisory committee [1][10]. - The company has disclosed relevant information on the Shanghai Stock Exchange, ensuring compliance with legal requirements [2][6]. Adjustments to the Incentive Plan - The number of initial incentive objects was adjusted from 216 to 214, and the total number of restricted stocks from 2,739,250 to 2,731,250 shares [5][12]. - The grant price was adjusted from 28.28 yuan to 27.78 yuan per share based on the second extraordinary general meeting of shareholders [6][14]. Compliance with Grant Conditions - The board confirmed that both the company and the incentive objects meet all necessary conditions for the grant, with no disqualifying circumstances present [7][9]. - The supervisory committee has verified the eligibility of the incentive objects and provided a clear opinion on the matter [10][14]. Accounting Treatment and Performance Impact - The fair value of the restricted stock will be calculated using the Black-Scholes model, and the associated costs will be recognized over the vesting period [13][14]. - The estimated total expense for the stock grant will impact the company's net profit during the vesting period, but the plan is expected to enhance long-term performance by motivating key employees [13][14].

Group 1 - The core point of the article is that Jingfeng Mingyuan (SH 688368) announced the convening of its 30th board meeting on August 26, 2025, to discuss the appointment of the board secretary and other documents [1] - For the fiscal year 2024, Jingfeng Mingyuan's revenue composition is 99.94% from integrated circuits and 0.06% from other businesses [1] - As of the report date, Jingfeng Mingyuan has a market capitalization of 9.1 billion yuan [1] Group 2 - The pet industry is experiencing significant growth, with a market size of 300 billion yuan, leading to a surge in stock prices for related companies [1]

Group 1 - The board of directors of Shanghai Jingfeng Mingyuan Semiconductor Co., Ltd. held its 30th meeting on August 26, 2025, with all 7 directors participating in the voting, confirming the legality and validity of the meeting procedures [1] - The board approved the adjustment of the grant price for the 2024 restricted stock incentive plan from RMB 28.28 per share to RMB 27.78 per share, with 6 votes in favor [2][3] - The board also approved the granting of reserved restricted stocks to 53 incentive objects at the adjusted price of RMB 27.78 per share, with the grant date set for August 26, 2025 [3] Group 2 - The board appointed Mr. Yang Biao as the secretary of the board, with a term lasting until the end of the current board's tenure, receiving unanimous approval from all 7 directors [3]

证券代码：688368 证券简称：晶丰明源 公告编号：2025-063 上海晶丰明源半导体股份有限公司 第三届监事会第二十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 具 体 内 容 详 见 公 司 于 2025 年 8 月 27 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）上披露的《上海晶丰明源半导体股份有限公司关于调整 2024 年限制性股票激励计划授予价格的公告》。 （二）审议通过《关于向 2024 年限制性股票激励计划激励对象授予预留部 分限制性股票的议案》 一、监事会会议召开情况 上海晶丰明源半导体股份有限公司（以下简称"公司"）第三届监事会第二 十七次会议于 2025 年 8 月 22 日以电子邮件、专人送达等方式通知了全体监事， 会议于 2025 年 8 月 26 日以现场会议方式召开。 会议由监事会主席李宁先生主持，会议应参加表决监事 3 人，实际参加表决 监事 3 人。本次监事会会议的召集和召开程序符合有关法律、行政法规、部门规 章、规范性文件和《上海晶 ...

Core Points - The company has appointed Mr. Yang Biao as the new Secretary of the Board of Directors, effective immediately upon approval by the board [1] - Mr. Yang has the necessary qualifications and experience to fulfill the role, having completed the required training and not being subject to any disqualifications under relevant laws [1][3] - The previous acting Secretary of the Board, Mr. Hu Liqiang, will no longer serve in that capacity [1] Summary of Related Sections - **Appointment Details**: The board of directors approved the appointment of Mr. Yang Biao as the Secretary of the Board, with his term lasting until the end of the third board's term [1] - **Qualifications**: Mr. Yang holds a bachelor's degree and has extensive experience in the semiconductor industry, having worked in various roles within the company since 2012 [3] - **Ownership and Relationships**: Mr. Yang directly holds 36,000 shares of the company and has no related party relationships with major shareholders or other board members [3]

Group 1: Zhaoyi Innovation - Zhaoyi Innovation reported good growth across all business lines in Q2 2024, with NOR Flash growing in the high single digits, niche DRAM growing over 50%, and MCU close to 20% [1] - The company expects significant revenue growth in niche DRAM in the second half of the year, with contract prices continuing to rise [1] - The demand for NOR Flash is increasing due to a rise in electronic product code volume, while supply remains tight due to wafer manufacturing capacity constraints [1] Group 2: Teabo Bio - Teabo Bio is focusing on functional cure for hepatitis B through a combination of different mechanism drugs with interferons and nucleoside analogs [2] - The company aims to provide comprehensive management of hepatitis B through a wide-reaching clinical cure network [2] - Collaboration with Ligos is underway to explore reinfection control after clearing infected cells [2] Group 3: Ruijie Networks - Ruijie Networks saw significant revenue growth in data center products, primarily driven by internet clients, with over 90% of revenue coming from this sector [3] - The company anticipates continued strong demand for cloud computing infrastructure in the second half of the year [3] - The gross margin for data center products is relatively low (15%-20%), while margins in enterprise and SMB markets have improved [3] Group 4: Trina Solar - Trina Solar is focusing on maintaining fair competition in the photovoltaic industry and promoting healthy development [4] - The company aims for over 8GWh in the storage segment for the year, with an increasing proportion of overseas orders [4] - The demand in the U.S. market is accelerating, leading to increased component prices and optimized supply chains [4] Group 5: Liangxin Co. - Liangxin Co. has segmented its data center business into three main areas: internet enterprises, operators, and individual projects, with a focus on HVDC and UPS [5] - The company is expected to continue its efforts in digital energy and infrastructure despite a potential slowdown in the renewable energy sector [5] - The gross margin for overseas business has slightly decreased compared to the previous year [5] Group 6: Baillie Tianheng - Baillie Tianheng is advancing three key overseas clinical trials for treating triple-negative breast cancer, EGFR-mutant non-small cell lung cancer, and urothelial carcinoma [6] - The company has submitted its first nuclear medicine candidate drug for domestic IND application [6] - R&D expenses reached 1.038 billion yuan by mid-year, with expectations for future clinical research costs to increase [6] Group 7: Jingfeng Mingyuan - Jingfeng Mingyuan has achieved an increase in overall gross margin through cost reduction and efficiency improvements [7] - The company is expanding its market presence in smart LED lighting products despite a decline in sales and prices in traditional LED lighting [7] - The high-performance computing power supply chip business has seen rapid growth, with products entering large-scale sales [7] Group 8: Chipone - Chipone is providing various customized hardware and software solutions in the AI field, serving multiple international giants [8] - The company has a high percentage of R&D personnel, with 89.31% of staff engaged in research and development [8] - Chipone is advancing Chiplet technology and has achieved success in designing high-performance automotive chips [8] Group 9: Xiasha Precision - Xiasha Precision reported a 30.77% increase in revenue for the first half of 2025, but a 41.87% decline in net profit due to price competition and rising costs [9] - The company plans to expand its product line in joint modules and increase R&D investment [9] - A new factory in Vietnam is under trial production, with plans to expand into overseas markets [9] Group 10: Lepu Medical - Lepu Medical's subsidiary focuses on elderly care services and has developed a facial filler product that has received regulatory approval [10] - The company is advancing AI products that monitor vital signs through various hardware applications [10] - Lepu Medical has a significant asset management scale, ranking 14th among 210 in public fund management [10]

Core Viewpoint - The stock price of Jingfeng Mingyuan reached 102.59 yuan as of August 25, 2025, showing a slight increase of 0.01 yuan or 0.01% from the previous trading day [1] Group 1: Company Performance - Jingfeng Mingyuan's main business involves the research, design, and sales of analog and mixed-signal integrated circuits, with applications in LED lighting, home appliances, and power management [1] - For the first half of 2025, the company reported a sales revenue of 731 million yuan and a net profit attributable to shareholders of 15.76 million yuan, marking an increase of 46.27 million yuan or 151.67% year-on-year [1] Group 2: Market Activity - On August 25, 2025, the company announced that it had received institutional research visits from several firms, including CITIC Securities, Bank of Communications Fund, and Guotai Fund, between August 18 and 22, focusing on the company's semi-annual performance [1] - Over the past year, the company has hosted 641 research visits from 403 institutions [1] Group 3: Capital Flow - On August 25, 2025, the net inflow of main funds was 9.35 million yuan, accounting for 0.1% of the circulating market value [1] - Over the past five days, the cumulative net outflow of main funds was 37.11 million yuan, representing 0.41% of the circulating market value [1]